This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Composit I Study Infographic

Prescribing Information

Discover how treatment with JANUVIA (Sitagliptin) during insulin therapy can benefit your patients with T2DM.1

Download a digital infographic of the CompoSIT-I study: A randomized clinical trial of the efficacy and safety of continuing sitagliptin when initiating insulin therapy in subjects with T2DM.

More than 11 years of experience:2 the evidence continues to build for JANUVIA (Sitagliptin)

Significantly greater reductions in HbA1c with JANUVIA compared to placebo

 

Mean daily insulin dose was significantly lower in the JANUVIA group compared to placebo

PDF 1,482 KB

 

This resource has been initiated, produced and the content of this infographic generated by MSD.

 

References:

  1. Roussel R, García SD, Zhang Y, et al. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study. Diabetes Obes Metab. 2018;1–10. https://doi.org/10.1111/dom.13574
  2. JANUVIA Summary of Product Characteristics

For more information about JANUVIA® (sitagliptin):

Supporting documentation

JANUVIA (Sitagliptin) 100 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

JANUVIA (Sitagliptin) 50 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

JANUVIA (Sitagliptin) 25 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-DIA-00720 | Date of Preparation: February 2020